Sansure Biotech (SHSE:688289) Other Stockholders Equity: ¥1,887 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688289 Sansure Biotech Inc SHSE:688289
69 GF Score
Price ¥15.69
GF Value ¥21.09
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Sansure Biotech Other Stockholders Equity?

Sansure Biotech SHSE:688289 +1.62% 69 Other Stockholders Equity is ¥1,887 Mil as of Mar. 2026. GuruFocus rates SHSE:688289 with a GF Score™ of 69/100 and a GF Value™ of ¥21.09 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Sansure Biotech's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ¥1,887 Mil.

Sansure Biotech's quarterly Other Stockholders Equity declined from Sep. 2025 (¥1,933 Mil) to Dec. 2025 (¥369 Mil) but then increased from Dec. 2025 (¥369 Mil) to Mar. 2026 (¥1,887 Mil).

Sansure Biotech's annual Other Stockholders Equity increased from Dec. 2023 (¥395 Mil) to Dec. 2024 (¥398 Mil) but then declined from Dec. 2024 (¥398 Mil) to Dec. 2025 (¥369 Mil).

Sansure Biotech Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Sansure Biotech's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sansure Biotech Other Stockholders Equity Chart

Sansure Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 293.95 377.42 395.21 398.25 368.76

Sansure Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,935.05 398.86 1,933.14 368.76 1,887.36
SHSE:688289
69GF Score
Sansure Biotech Inc SHSE:688289
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sansure Biotech Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ¥1,887 Mil mean?
Sansure Biotech (SHSE:688289) has a Other Stockholders Equity of ¥1,887 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Sansure Biotech and its competitors.
Is Sansure Biotech's Other Stockholders Equity too high?
Sansure Biotech's current Other Stockholders Equity is ¥1,887 Mil. Overall, Sansure Biotech has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sansure Biotech's Other Stockholders Equity compare to ISRG and BDX?
Sansure Biotech's Other Stockholders Equity of ¥1,887 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Sansure Biotech and its competitors. Sansure Biotech's current Other Stockholders Equity is ¥1,887 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sansure Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sansure Biotech (SHSE:688289) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥21.09, compared to a current price of ¥15.69 — trading 25.6% below its estimated fair value. The current Other Stockholders Equity is ¥1,887 Mil. Sansure Biotech's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Sansure Biotech (SHSE:688289), the current Other Stockholders Equity is ¥1,887 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sansure Biotech (SHSE:688289) Overvalued in 2026?

Based on GuruFocus' analysis, Sansure Biotech stock appears to be undervalued. The current stock price of ¥15.69 is trading 25.6% below its estimated GF Value™ of ¥21.09. GuruFocus considers Sansure Biotech to be Modestly Undervalued.

Key valuation signals for SHSE:688289:

  • Other Stockholders Equity: ¥1,887 Mil
  • GF Value™: ¥21.09 vs. price of ¥15.69 (25.6% below fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688289 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sansure Biotech Business Description

Address No. 680, Lusong Road, Changsha High-tech Industrial Development Zone, Hunan Province, Changsha, CHN, 410205
Sansure Biotech Inc is engaged in the Research, development, production, and sales of diagnostic reagents and instruments.
69GF Score

Get the complete analysis for SHSE:688289

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.69
Price
¥21.09
GF Value